4.7 Article

An Integrated Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide Study): Rationale, Study Design and Pilot Study

期刊

JOURNAL OF PERSONALIZED MEDICINE
卷 12, 期 7, 页码 -

出版社

MDPI
DOI: 10.3390/jpm12071074

关键词

endometrial cancer; ovarian cancer; early detection; pap smears; self-sampling; genomic

资金

  1. Carlos III Health Institute [PIE16/0049, PI17/01179, PI19/01835, CM19/00216, FI20/00031, MV20/00029, MV21/00061]
  2. European Regional Development Fund ERDF, a way to build Europe
  3. Secretariat for Universities and Research of the Department of Business and Knowledge of the Generalitat de Catalunya
  4. Roche Diagnostics
  5. AECC Grupos estables coordinados [2017SGR01085, 2017SGR01718, 2017SGR1282, 2017SGR00735]
  6. Health Department of the Generalitat de Catalunya [PERIS SLT006/17/76]
  7. [CIBERESP CB06/02/0073]
  8. [CIBERONC CB16/12/00401]
  9. [CB16/12/00234]
  10. [PID2019-111254RB-I00]

向作者/读者索取更多资源

Screenwide is a four-year case-control study aimed at evaluating potential risk factors for endometrial and ovarian cancers, as well as developing early detection strategies. The results of the study showed that genetic variants in the samples could be detected through various methods for early detection, suggesting the potential application of this approach in clinical practice.
Screenwide is a case-control study (2017-2021) including women with incident endometrial and ovarian cancers (EC and OC), BRCA1/2 and MMR pathogenic variant carriers, and age-matched controls from three centers in Spain. Participants completed a personal interview on their sociodemographic factors, occupational exposure, medication, lifestyle, and medical history. We collected biological specimens, including blood samples, self-collected vaginal specimens, cervical pap-brush samples, uterine specimens, and, when available, tumor samples. The planned analyses included evaluation of the potential risk factors for EC/OC; evaluation of molecular biomarkers in minimally invasive samples; evaluation of the cost-effectiveness of molecular tests; and the generation of predictive scores to integrate different epidemiologic, clinical, and molecular factors. Overall, 182 EC, 69 OC, 98 BRCA pathogenic variant carriers, 104 MMR pathogenic variant carriers, and 385 controls were enrolled. The overall participation rate was 85.7%. The pilot study using 61 samples from nine EC cases and four controls showed that genetic variants at the variant allele fraction > 5% found in tumors (n = 61 variants across the nine tumors) were detected in paired endometrial aspirates, clinician-collected cervical samples, and vaginal self-samples with detection rates of 90% (55/61), 79% (48/61), and 72% (44/61) by duplex sequencing, respectively. Among the controls, only one somatic mutation was detected in a cervical sample. We enrolled more than 800 women to evaluate new early detection strategies. The preliminary data suggest that our methodological approach could be useful for the early detection of gynecological cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据